Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 4/20 | 1.00 |
| ▸ | RET | P07949 | 3/20 | 0.79 |
| ▸ | HIPK4 | Q8NE63 | 3/20 | 0.79 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.79 |
| ▸ | PLK4 | O00444 | 2/20 | 0.79 |
| ▸ | AURKA | O14965 | 2/20 | 0.79 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.79 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.79 |
| ▸ | ABL1 | P00519 | 2/20 | 0.79 |
| ▸ | LCK | P06239 | 2/20 | 0.79 |
| ▸ | FYN | P06241 | 2/20 | 0.79 |
| ▸ | LYN | P07948 | 2/20 | 0.79 |
| ▸ | SRC | P12931 | 2/20 | 0.79 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.79 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.79 |
| ▸ | AXL | P30530 | 2/20 | 0.79 |
| ▸ | FRK | P42685 | 2/20 | 0.79 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.79 |
| ▸ | BLK | P51451 | 2/20 | 0.79 |
| ▸ | CAMK2B | Q13554 | 2/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19878581 | 1.00 | KDR (1.00) | KDRRETHIPK4MAPK14PLK4 | |
| SCHEMBL5420458 | 0.91 | KDR (0.83) | KDRRETHIPK4MAPK14PLK4 | |
| SCHEMBL14684305 | 0.91 | KDR (0.83) | KDRRETHIPK4MAPK14PLK4 | |
| SCHEMBL5427402 | 0.90 | KDR (0.82) | KDRRETHIPK4MAPK14PLK4 | |
| SCHEMBL14684309 | 0.90 | KDR (0.81) | KDRRETHIPK4MAPK14PLK4 | |
| SCHEMBL14527450 | 0.89 | KDR (0.80) | KDRRETHIPK4MAPK14PLK4 | |
| SCHEMBL16628085 | 0.88 | KDR (1.00) | KDRRETHIPK4MAPK14PLK4 | |
| SCHEMBL19878491 | 0.87 | KDR (0.78) | KDRRETHIPK4MAPK14PLK4 | |
| SCHEMBL14527432 | 0.87 | KDR (0.76) | KDRRETHIPK4MAPK14PLK4 | |
| SCHEMBL21124526 | 0.86 | KDR (0.85) | KDRRETHIPK4MAPK14PLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117919415-A | Application of FGFR inhibitor in diabetes combined coronavirus infection | 广州国家实验室 | 2024-04-26 | — | — | CN | claimed |
| CN-114585356-A | Methods of preventing or treating diseases associated with VEGFR and/or VEGF inhibition | 上海岸阔医药科技有限公司 | 2022-06-03 | — | — | CN | claimed |
| CN-114028568-A | Method for preventing or treating side effects of tumor therapy | 上海岸阔医药科技有限公司 | 2022-02-11 | — | — | CN | claimed |
| CN-113975264-A | Method for preventing or treating side effects of tumor therapy | 上海岸阔医药科技有限公司 | 2022-01-28 | — | — | CN | claimed |
| CN-122094689-A | Combination therapy of diacylglycerol kinase (DGK) alpha inhibitors with other therapies | — | 2026-05-26 | — | — | CN | disclosed |
| EP-4739310-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) INHIBITOR COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-05-13 | — | — | EP | disclosed |
| EP-4615869-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | Pinetree Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| US-20250283077-A1 | ENHANCED HAMMERHEAD RIBOZYMES AND METHODS OF USE | US GOV VETERANS AFFAIRS (US) | 2025-09-11 | — | — | US | disclosed |
| EP-4578459-A1 | PHARMACEUTICAL PRODUCT FOR TREATMENT AND/OR PREVENTION OF CANCER | Toray Industries, Inc. (JP) | 2025-07-02 | — | — | EP | disclosed |
| US-20250170090-A1 | METHOD FOR PREVENTING OR TREATING DISEASE OR DISORDER ASSOCIATED WITH ANTINEOPLASTIC AGENT | ONQUALITY PHARMACEUTICALS CHINA LTD (CN) | 2025-05-29 | — | — | US | disclosed |
| CN-119744176-A | Medicine for treating and/or preventing cancer | 东丽株式会社 | 2025-04-01 | — | — | CN | disclosed |
| WO-2025051110-A1 | COMBINATIONS TREATMENTS OF DIACYLGLYCEROL KINASE (DGK) ALPHA INHIBITORS AND OTHER THERAPIES | INSILICO MEDICINE IP LIMITED (CN) | 2025-03-13 | — | — | WO | disclosed |
| WO-2023142996-A1 | METHOD FOR PREVENTING OR TREATING DISEASE OR DISORDER ASSOCIATED WITH ANTINEOPLASTIC AGENT | 上海岸阔医药科技有限公司 | 2023-08-03 | — | — | WO | disclosed |
| WO-2023127909-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING ARTERIAL ANEURYSM, METHOD FOR ASSISTING DIAGNOSIS OF ARTERIAL ANEURYSM, AND METHOD FOR ASSESSING THERAPEUTIC DRUG FOR ARTERIAL ANEURYSM | 国立研究開発法人理化学研究所 | 2023-07-06 | — | — | WO | disclosed |
| CN-116211789-A | Composition and use thereof | 上海岸阔医药科技有限公司 | 2023-06-06 | — | — | CN | disclosed |
| WO-2023062115-A1 | METHODS FOR DETERMINING THE LIKELIHOOD OF A MALIGNANT DISEASE RESPONDING TO TREATMENT WITH A PHARMACEUTICAL INHIBITOR | Rheinische Friedrich-Wilhelms-Universität Bonn (DE) | 2023-04-20 | — | — | WO | disclosed |
| CN-115068620-A | Pharmaceutical composition capable of reducing generation of arylamine impurities | 天津睿创康泰生物技术有限公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-114585356-A | Methods of preventing or treating diseases associated with VEGFR and/or VEGF inhibition | 上海岸阔医药科技有限公司 | 2022-06-03 | — | — | CN | disclosed |
| CN-114028568-A | Method for preventing or treating side effects of tumor therapy | 上海岸阔医药科技有限公司 | 2022-02-11 | — | — | CN | disclosed |
| CN-113975264-A | Method for preventing or treating side effects of tumor therapy | 上海岸阔医药科技有限公司 | 2022-01-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250170090-A1 | METHOD FOR PREVENTING OR TREATING DISEASE OR DISORDER ASSOCIATED WITH ANTINEOPLASTIC AGENT | VHL, SLC10A1, NNMT | KDR 4883/4885RET 4420/4885HIPK4 1775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.